Selected Antineoplastic Systemic Enzyme Inhibitors/ Grapefruit or Seville Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug, changing your diet or commencing any course of treatment.

Medical warning:

Very important. A change in your diet, medicine, or dosage may be necessary. Promptly consult your doctor or pharmacist.

How the interaction occurs:

Grapefruit and Seville oranges may slow down how quickly your body processes your cancer medicine.

What might happen:

The amount of your cancer medicine in your blood may increase and cause more side effects than normal.

What you should do about this interaction:

While you are taking this medicine, you should not eat grapefruit or drink grapefruit juice or eat Seville oranges (often found in marmalades) at any time. You may choose an alternative citrus (such as non-Seville oranges). In the event that you are instructed by a healthcare professional (e.g., doctor, pharmacist, or dietitian) to eat grapefruit or drink grapefruit juice, you should immediately discuss with your doctor the effects of grapefruit on the blood levels of this medicine.Contact your healthcare professional (e.g., doctor or pharmacist) for more information.Your healthcare professionals may be aware of this interaction and may be monitoring you for it. Do not start, stop, or change your medicine or diet before checking with them first.

  • 1.Inlyta (axitinib) US prescribing information. Pfizer Inc. August, 2018. 2.Bosulif (bosutinib) US prescribing information. Pfizer Inc. November 18, 2018.
  • 2.Cometriq (cabozantinib) US prescribing information. Exelixix, Inc. January, 2018.
  • 3.Zykadia (ceritinib) US prescribing information. Novartis Pharmaceuticals Corporation March, 2019.
  • 4.Xalkori (crizotinib) US prescribing information. Pfizer Inc. June, 2019. 6.Tafinlar (dabrafenib) US prescribing information. Novartis Pharmaceuticals Corporation July, 2019.
  • 5.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company November 19, 2017.
  • 6.Tarceva (erlotinib) US prescribing information. Genentech, Inc. October, 2016.
  • 7.Imbruvica (ibrutinib) US Prescribing information. Pharmacyclics, Inc. July, 2019.
  • 8.Zydelig (idelalisib) US prescribing information. Gilead Sciences, Inc. October, 2018.
  • 9.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline January 29, 2010.
  • 10.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation March, 2018.
  • 11.Votrient (pazopanib) US prescribing information. GlaxoSmithKline May, 2017.
  • 12.Sutent (sunitinib malate) US prescribing information. Pfizer Labs. January, 2006.
  • 13.Ibrance (palbociclib) US prescribing information. Pfizer Labs April, 2019.
  • 14.Lynparza (olaparib) capsules US prescribing information. AstraZenica Pharmaceuticals October 23, 2017.
  • 15.Lorbrena (lorlatinib) US prescribing information. Pfizer Inc. November 2018.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.